Mazdutide

Mazdutide is a new generation peptide drug designed to tackle obesity and type 2 diabetes. To put it in perspective with familiar medications: semaglutide activates only the GLP-1 receptor, and tirzepatide activates both GLP-1 and GIP receptors. Mazdutide, however, takes a different route by targeting GLP-1 and glucagon. This specific combination not only suppresses appetite but actively increases the body's energy expenditure, leading to up to 20.1 % body weight loss in clinical trials.

What is mazdutide?

Mazdutide is an investigational peptide drug and dual receptor agonist developed for the treatment of obesity and type 2 diabetes. Known under the development codes IBI362 and LY3305677, it mimics a natural gut hormone to deliver significant weight loss, though clinical data is predominantly sourced from Chinese populations and it is currently only approved in China.

Originally discovered and developed by Eli Lilly, mazdutide was licensed to Innovent Biologics in 2019, granting the company exclusive rights for its further development and commercialization in China. It belongs to the oxyntomodulin family and is chemically modified with a fatty acid chain. This protective coat slows down its breakdown in the body, giving it a half-life of approximately 6 to 7 days. This extended half-life makes it highly convenient for patients, as it requires only a once-weekly subcutaneous injection under the skin.

How does mazdutide work?

Mazdutide works by simultaneously activating two distinct metabolic receptors in the body: the GLP-1 receptor, which controls appetite and blood sugar, and the glucagon receptor, which increases energy expenditure. This dual action closely mimics the natural mammalian gut hormone oxyntomodulin (OXM), providing a two-pronged approach to metabolic health.

• GLP-1 receptor activation: Suppresses hunger signaling in the hypothalamus, slows gastric emptying (making you feel full longer), and stimulates glucose-dependent insulin secretion. This means it only releases insulin when blood sugar is actually elevated.
• Glucagon receptor activation: Directly raises resting energy expenditure and stimulates the breakdown of fat (lipolysis). It also reduces fat accumulation in the liver. This added fat-burning engine is what separates mazdutide from pure GLP-1 agonists.

How effective is mazdutide?

Mazdutide has demonstrated highly significant clinical effectiveness by producing up to 20.1 % weight loss in adults with obesity during Phase 3 trials. It also effectively lowers long-term blood sugar markers in type 2 diabetes patients, alongside notable secondary benefits like reductions in waist circumference, blood pressure, triglycerides, and liver fat.

However, a critical limitation regarding this effectiveness must be noted: nearly all available clinical data stems exclusively from trials conducted on Chinese adults. While the metabolic mechanisms are biologically universal, the direct transferability of these exact weight loss percentages and safety profiles to Western or diverse global populations is not yet backed by published head-to-head multi-ethnic trials.

The GLORY and DREAMS study program

The GLORY and DREAMS clinical study programs represent a massive research effort, encompassing 17 different clinical trials that have enrolled over 1,500 participants. These ongoing programs are specifically evaluating mazdutide's safety and efficacy across obesity, type 2 diabetes, and emerging metabolic indications like fatty liver disease and heart failure.

The data is heavily anchored by GLORY-1, whose results were published in The Lancet Diabetes & Endocrinology. In GLORY-1, participants receiving 4 mg and 6 mg doses experienced weight loss between 10 % and 12.5 % after 32 weeks. Meanwhile, the GLORY-2 study tested a higher 9 mg dose, achieving a massive 20.1 % body weight reduction. For type 2 diabetes, the DREAMS Phase 3 trials successfully met their primary endpoints, with results published in Nature Medicine.

Dosage: what the studies show - and the course

Clinical studies utilize a carefully structured, step-wise titration protocol for mazdutide, involving once-weekly subcutaneous injections. This gradual dose escalation is critically important for allowing the gastrointestinal system to adapt, thereby minimizing the severe nausea and vomiting commonly associated with starting higher doses immediately.

The clinical development program evaluated doses ranging from 3 mg up to 10 mg. A Phase 2 trial specifically highlighted that for individuals with a higher baseline body mass index (BMI over 30 kg/m²), extending the treatment duration beyond the standard 24 weeks is often necessary to achieve the maximum targeted weight loss goals.

Mixing & calculating dose

Mixing and calculating the dose - this section is only relevant for research-grade material. Because mazdutide is not sold as a ready-to-use injection pen outside China, some people obtain the active ingredient as a freeze-dried powder (called lyophilized powder) from unregulated sources. To inject it, the powder must first be dissolved in a sterile water solution (often labelled 'bacteriostatic water'). The example below shows how to calculate the required volume. Please note: this information serves as harm reduction for people who nevertheless handle research material - it is not a substitute for a pharmacy-prepared pen (a so-called pharmaceutical-grade, pre-measured injection pen).

Because mazdutide is administered as a subcutaneous injection, proper handling and reconstitution are vital if utilizing this research-grade lyophilized powder. This process requires sterile bacteriostatic water and precise mathematical calculations to ensure the intended dose matches the exact volume of the reconstituted solution, avoiding dangerous dosing errors.

For individuals using non-commercial research peptides, calculating the correct dose involves dividing the desired dose (e.g., 5 mg) by the total amount of peptide in the vial (e.g., 10 mg), then multiplying by the total volume of bacteriostatic water used (e.g., 2 ml). This strict protocol serves as informational harm reduction and is not a substitute for pharmaceutical-grade, pre-measured injection pens.

Side effects and common mistakes

The side effects of mazdutide are predominantly gastrointestinal in nature and can be severe, with clinical meta-analyses showing drastically increased risks of nausea, vomiting, and decreased appetite compared to a placebo. Understanding these risks is essential to avoid early treatment discontinuation and ensure proper harm reduction during the titration phase.

According to pooled clinical data, the relative risks (RR) for adverse events are substantial. Patients taking mazdutide have a 4.22 times higher risk of experiencing nausea, a 4.91 times higher risk of vomiting, and a 2.30 times higher risk of appetite loss compared to those taking a placebo. Diarrhea, abdominal distension, and increased heart rate were also frequently observed at higher 9 mg doses.

• Skipping titration: Starting directly at a high dose (like 6 mg or 9 mg) almost guarantees severe nausea and vomiting. The body must adapt gradually.
• Ignoring hydration: Severe gastrointestinal distress, particularly vomiting and diarrhea, can rapidly lead to dehydration, which stresses the kidneys and cardiovascular system.
• Sourcing unregulated products: Because mazdutid lacks global approval, buying peptide vials online carries massive risks of bacterial contamination, impure active ingredients, or incorrect dosing.

Regulatory status and legal situation

The regulatory status of mazdutide is currently restricted, having received official medical approval exclusively in China for weight management and type 2 diabetes. It has not been approved by the European Medicines Agency or the US Food and Drug Administration, meaning its commercial sale and medical use are strictly illegal in Western markets.

As of 2026, the massive clinical data volume has only secured approval from China's National Medical Products Administration (NMPA), granted in 2024. For individuals in the USA (FDA) and the European Union (EMA), mazdutide remains an unauthorized investigational drug. Any purchase outside of official Chinese pharmacies occurs entirely on the unregulated grey market, presenting significant legal and health hazards.